Literature DB >> 7471913

Chemotherapy of pediatric posterior fossa tumors.

M S Edwards, V A Levin, C B Wilson.   

Abstract

Results of chemotherapy of recurrent posterior fossa tumors in children are presented. Cerebellar astrocytoma, ependymoma, and brain stem glioma have all shown objectively determined responses to treatment with nitrosourea compounds (BCNU or CCNU). Medulloblastoma has shown objectively determined response to various chemotherapeutic agents; but in our experience the best responses have been obtained with a combination of a nitrosourea (CCNU), vincristine, and procarbazine. Although chemotherapy after recurrence has significantly prolonged the life of the patients, cure has not been achieved. Theoretical considerations regarding the failure of initial therapy and the inadequacy of subsequent chemotherapy are discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7471913     DOI: 10.1159/000119952

Source DB:  PubMed          Journal:  Childs Brain        ISSN: 0302-2803


  5 in total

1.  Prognostic relevance of localization and grading in intracranial ependymomas of childhood.

Authors:  R I Ernestus; R Schröder; H Stützer; N Klug
Journal:  Childs Nerv Syst       Date:  1996-09       Impact factor: 1.475

Review 2.  Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy.

Authors:  M T Jennings; M L Freeman; M J Murray
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

Review 3.  Spinal metastases of intracranial ependymomas. Four case reports and review of the literature.

Authors:  R I Ernestus; O Wilcke
Journal:  Neurosurg Rev       Date:  1990       Impact factor: 3.042

4.  Cerebellar astrocytomas in childhood.

Authors:  C Lapras; J D Patet; C Lapras; C Mottolese
Journal:  Childs Nerv Syst       Date:  1986       Impact factor: 1.475

5.  Remarks on the follow-up of cerebellar astrocytomas.

Authors:  A Ferbert; F Gullotta
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.